Evidence map›Paper›PMID 38579764›Full record

ReviewThe Journal of endocrinology2024

FSH, bone, belly and brain.

Se-Min Kim, Farhath Sultana, Steven Sims, Judit Gimenez-Roig, Victoria Laurencin, Anusha Pallapati, Satish Rojekar, Tal Frolinger, Weibin Zhou, Anisa Gumerova and 6 more

Abstract readReview
In one paragraph

Review in The Journal of endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Se-Min KimThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Farhath SultanaThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Steven SimsThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Judit Gimenez-RoigThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Victoria LaurencinThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Anusha PallapatiThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Satish RojekarThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Tal FrolingerThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Weibin ZhouThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Anisa GumerovaThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Anne MacdonaldThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Vitaly RyuThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Daria LiznevaThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Funda KorkmazThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Tony YuenThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.
Mone ZaidiThe Mount Sinai Bone Program, Departments of Pharmacological Sciences and Medicine, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine, Mount Sinai, New York, USA.ORCID 0000-0001-5911-9522

Funding

Targeting FSH for the Therapy of Osteoporosis, Obesity and NeurodegenerationU19AG060917 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Mone Zaidi · 2019 to 2026
$29.0M
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's DiseaseU01AG073148 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Tony Yuen, Mone Zaidi · 2021 to 2026
$10.6M
Elevated FSH - A Driver for Sex Differences in Alzheimer's DiseaseR01AG074092 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAROUTUNIAN, VAHRAM, YUEN, TONY · 2021 to 2025
$6.3M
Proof-of-Concept and Mechanistic Studies to Repurpose Erectile Dysfunction Drugs for Elderly FemalesR01AG071870 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KIM, SE-MIN, YUEN, TONY · 2021 to 2025
$3.9M
Thyrotropin Receptor, Thyrotropin and Mechanisms of Bone LossR01DK113627 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DAVIES, TERRY FRANCIS, IQBAL, JAMEEL Z · 2017 to 2020
$2.8M
NIA NIH HHS R01 AG071870NIA NIH HHS R01 AG074092NIA NIH HHS U01 AG073148NIA NIH HHS U19 AG060917NIDDK NIH HHS R01 DK113627
6 · The paper itself

Abstract

The pituitary gland orchestrates multiple endocrine organs by secreting tropic hormones, and therefore plays a significant role in a myriad of physiological processes, including skeletal modeling and remodeling, fat and glucose metabolism, and cognition. Expression of receptors for each pituitary hormone and the hormone itself in the skeleton, fat, immune cells, and the brain suggest that their role is much broader than the traditionally attributed functions. FSH, believed solely to regulate gonadal function is also involved in fat and bone metabolism, as well as in cognition. Our emerging understanding of nonreproductive functions of FSH, thus, opens potential therapeutic opportunities to address detrimental health consequences during and after menopause, namely, osteoporosis, obesity, and dementia. In this review, we outline current understanding of the cross-talk between the pituitary, bone, adipose tissue, and brain through FSH. Preclinical evidence from genetic and pharmacologic interventions in rodent models, and human data from population-based observations, genetic studies, and a small number of interventional studies provide compelling evidence for independent functions of FSH in bone loss, fat gain, and congnitive impairment.

Indexed as

Bone and BonesBrainFollicle Stimulating HormoneAdipose TissueAnimalsHumansOsteoporosisPituitary GlandFollicle Stimulating HormonebonebrainfatFSHpituitary

Identifiers

PMID38579764
PMCPMC12991055

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.